CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial - RATIONAL-PT
Feasibility, Acceptability and Representativeness: Collecting Sociodemographic Data in CCTG Trials
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
The CCTG Annual Spring Meeting is only 6 weeks away! Don't forget that the request an invitation portal closes April 7 and online registration closes April 9.
Primary Publication
CCTG will be holding the next CRA Lunch and Learn on Wednesday March 26th, 2025, at 12 pm ET. Session 4 will cover the topic of Introduction to RIPPLE: CCTG's rostering and participants list system
The Canadian Cancer Trials Group (CCTG) is currently seeking applications for a Patient Representative for the Gastro-Intestinal Disease Site Committee. CCTG is an inclusive organization dedicated to building a diverse network. This is a volunteer role for membership on the Gastro-Intestinal Disease Site Committee, the Gastro-Intestinal Disease Site Executive Committee, and the CCTG Patient Representative Committee.
The CCTG Annual Spring Meeting of Participants is fast approaching! We are excited to share important updates and additional information.
This pivotal study is a move away from current ‘one size fits all’ treatment approaches through the testing of a vulvar cancer patients’ tissue to determine the best treatment options. Researchers want to evaluate if the molecular features in tissues removed in the first surgery can direct the need for additional surgery versus a close follow-up for patients with vulvar squamous cell cancer.
